Disturbed Lipids, Lipoproteins and Triglyceride-Rich Lipoproteins as Well as Fasting and Nonfasting Non-High–Density Lipoprotein Cholesterol in Post-Renal Transplant Patients

Figures & data

Table 1 Clinical and laboratory parameters is post–renal transplant patients

	Patients with dyslipidemia (n = 69)	Patients with normolipidemic (n = 29)
Age, years	46.04 ± 11.26	42.29 ± 13.63
Sex (male, female)	37 M, 32 F	14 M, 15 F
BMI kg/m^2	25.98 ± 4.60	23.83 ± 3.35
Time after transplant (month)	37.50 ± 36.25	40.08 ± 31.07
GFR	64.89 ± 22.33	64.02 ± 18.90
Urea, mg/dL	52.70 ± 25.27	50.08 ± 24.99
Creatinine, mg/dL	1.68 ± 0.68	1.63 ± 0.85
Total protein, g/dL	7.10 ± 0.52	7.05 ± 0.57
Albumin, g/dL	4.20 ± 0.29	4.27 ± 0.32
Hemoglobin, mg/dL	13.73 ± 1.77	14.23 ± 1.28

Figure 1. Regression and Bland-Altman analysis for non-HDL cholesterol (Pearson's coeff. corr. R = 0.987, coeff.determ. R² = 0.987).

Table 2 Fasting lipid and lipoprotein profiles and lipid and lipoprotein ratios

	Reference group (n = 87)	All patients group (n = 98)	Patients with dyslipidemia (n = 69)	Patients with normolipidemic (n = 29)
TG mg/dL	91.67 ± 28.08	174.47 ± 54.99***	192.20 ± 52.26***	132.31 ± 35.00**^††
TC mg/dL	184.29 ± 26.63	198.97 ± 27.45	203.35 ± 28.88	188.62 ± 20.61
LDL-C mg/dL	104.50 ± 23.56	122.99 ± 21.61	126.93 ± 22.55	113.62 ± 15.91
HDL-C mg/dL	57.58 ± 7.93	41.08 ± 9.25***	37.98 ± 7.67***	48.51 ± 8.63^††
Non-HDL-C mg/dL	126.71 ± 24.06	156.94 ± 24.89**	164.12 ± 24.34**	140.12 ± 17.00^††
ApoAI mg/dL	155.53 ± 14.89	152.57 ± 13.96	150.13 ± 22.15	153.28 ± 14.12
ApoB mg/dL	73.55 ± 15.96	90.06 ± 17.53	91.85 ± 17.64	85.17 ± 16.34
ApoCIII mg/dL	2.65 ± 0.54	4.99 ± 1.58***	5.34 ± 1.54***	4.04 ± 1.26**^†
ApoCIIInonB mg/dL	1.98 ± 0.47	2.84 ± 0.95**	2.91 ± 1.01**	2.64 ± 0.74**
ApoB:CIII mg/dL	0.68 ± 0.24	2.16 ± 1.19***	2.43 ± 1.16***	1.39 ± 0.92**^††
ApoE mg/dL	4.81 ± 1.41	6.36 ± 2.03	6.48 ± 2.06	6.04 ± 1.96
ApoEnonB mg/dL	3.72 ± 1.11	4.64 ± 1.48	4.72 ± 1.54	4.42 ± 1.38
ApoB:E mg/dL	1.14 ± 0.92	1.76 ± 1.25	1.79 ± 1.22	1.67 ± 1.35
TC/HDL-C	3.20 ± 0.61	5.04 ± 1.15***	5.50 ± 1.03***	3.96 ± 0.57**^††
LDL-C/HDL-C	1.81 ± 0.60	3.20 ± 0.89***	3.45 ± 0.83***	2.40 ± 0.47**^††
TG/HDL-C	1.59 ± 0.61	4.51 ± 1.86***	5.22 ± 1.69***	2.82 ± 0.87***^††
ApoAI/apoB	2.12 ± 0.43	1.70 ± 0.52	1.63 ± 0.63	1.80 ± 0.59
ApoAI/apoCIII	58.69 ± 8.39	30.78 ± 9.78***	28.11 ± 9.98***	37.94 ± 9.02***^†

*p < 0.05, **p < 0.001, ***p < 0.001 vs. reference group.

^†p < 0.05, ^††p < 0.01 vs. dyslipidemia.

Table 3 Paired t-test analysis of fasting and nonfasting lipid profiles

	Patients with dyslipidemia (n = 69)		Mean difference	Patients with normolipidemic (n = 29)		Mean difference
	Fasting	Nonfasting		Fastin	Nonfasting
TG mg/dL	192.2 ± 52.2	232.7 ± 64.7	40.5	132.3 ± 35.0	168.5 ± 37.1	36.2
TC mg/dL	203.4 ± 28.9	202.0 ± 28.3	−1.3	188.6 ± 20.6	187.7 ± 20.8	−0.90
LDL-C mg/dL	126 ± 22.6	117.7 ± 20.6	−9.3	113.6 ± 15.9	105.8 ± 15.4	−7.9
HDL-C mg/dL	37.9 ± 7.7	37.8 ± 7.7	−0.31^†	48.5 ± 8.6	48.2 ± 8.4	−0.20
Non-HDL-C mg/dL	164.1 ± 24.3	163.0 ± 23.9	−1.2	140.1 ± 17.0	139.5 ± 17.1	−0.6
TC/HDL-C	5.50 ± 1.03	5.49 ± 1.03	−0.01	3.96 ± 0.57	3.96 ± 0.56	−0.01
LDL-C/HDL-C	3.45 ± 0.83	3.23 ± 0.82	−0.23	2.40 ± 0.47	2.24 ± 0.45	−0.16
TG/HDL-C	5.22 ± 1.69	6.31 ± 1.91	1.09	2.82 ± 0.87	3.59 ± 0.95	0.79

*p < 0.001, ^†p < 0.01.

Table 4 Linear regression between fasting and nonfasting lipids and lipid

	All patients (n = 98) (β)	R^2	Patients with dyslipidemia (n = 69) (β)	R^2	Patients with normolipidemic (n = 29) (β)	R^2
TG	0.895	0.802	0.883	0.779	0.771	0.579
TC	0.995	0.989	0.995	0.984	0.993	0.985
LDL-C	0.947	0.896	0.946	0.894	0.932	0.864
HDL-C	0.998	0.996	0.998	0.996	0.996	0.991
Non-HDL-C	0.994	0.987	0.993	0.985	0.989	0.978
TC/HDL-C	0.995	0.991	0.993	0.985	0.992	0.983
LDL-C/HDL-C	0.980	0.961	0.973	0.946	0.965	0.928
TG/HDL-C	0.944	0.891	0.921	0.846	0.835	0.696

β = coefficient of regression; R² = coefficient of determination.

Table 5 Pearson's correlation

	All patients (n = 98)		Patients with dyslipidemia (n = 69)		Patients with normolipidemic (n = 29)
	Non-HDL-C fasting	Non-HDL-C nonfasting	Non-HDL-C fasting	Non-HDL-C nonfasting	Non-HDL-C fasting	Non-HDL-C nonfasting
TG f	0.602	0.578	0.518	0.489	0.348	0.327
TG nonf	0.691	0.663	0.637	0.605	0.477	0.442
TC f	0.937	0.929	0.951	0.953	0.914	0.906
TC nonf	0.933	0.936	0.964	0.962	0.911	0.920
LDL-C f	0.903	0.908	0.905	0.911	0.911	0.909
LDL-C nonf	0.830	0.858	0.814	0.845	0.873	0.901
HDL-C f	−0.022	−0.029	0.294	0.278	0.221	0.223
HDL-C nonf	−0.016	−0.024	0.296	0.270	0.238	0.238
Non-HDL-C	—	0.994	—	0.993	—	0.989
TC/HDL-C f	0.588	0.586	0.423	0.433	0.487^†	0.484^†
TC/HDL-C nonf	0.563	0.576	0.395	0.417	0.476^†	0.488^†
LDl-C/HDL-C f	0.557	0.569	0.396	0.416	0.499^†	0.501^†
LDl-C/HDL-C nonf	0.484	0.509	0.294^†	0.331^†	0.475^†	0.502^†
TG/HDL-C f	0.465	0.453	0.287^†	0.271^†	0.235	0.222
TG/HDL-C nonf	0.544	0.529	0.404	0.387	0.288	0.262
ApoB	0.792		0.693		0.645
ApoCIII	0.368^†		0.226		0.171
ApoCIIInonB	0.282^‡		0.232		0.252
ApoB:CIII	0.261^‡		0.092		0.032
ApoE	0.118		0.066		0.091
ApoEnonB	0.096		0.085		−0.143
ApoB:E	0.043		0.025		0.051

coefficient correlation: r* = p < 0.001, r^† = p < 0.01, r^‡ = p < 0.05.

Abbreviations: f = fasting, nonf = nonfasting.